Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_assertion type Assertion NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_head.
- NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_assertion description "[However, there is reason for renewed optimism given the now very detailed knowledge of the cancer genome in GBM and a wealth of novel compounds entering the clinic, including next generation RTK inhibitors, class I PI3K inhibitors, mTOR kinase inhibitors (TORKinibs), and dual PI3(K)/mTOR inhibitors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_provenance.
- NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_assertion evidence source_evidence_literature NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_provenance.
- NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_assertion SIO_000772 22015553 NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_provenance.
- NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_assertion wasDerivedFrom befree-20150227 NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_provenance.
- NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_assertion wasGeneratedBy ECO_0000203 NP625570.RAShAQh19dwhCjd4SZeSR6kOLr4n9CPNbcK52rQIIf6d4130_provenance.